Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 89pembrolizumab 83Magnetic Resonance Spectroscopy 47Radiotherapy, Intensity-Modulated 41Specimen Handling 37Cetuximab 37Carboplatin 37Radiotherapy 36Nivolumab 29Paclitaxel 25Platinum 23Radiation 22Docetaxel 22Gemcitabine 21Biopsy 211,2-diaminocyclohexaneplatinum II citrate 21Surveys and Questionnaires 17Fluorouracil 14toripalimab 13Standard of Care 13Taxes 11Cyclophosphamide 10cemiplimab 9atezolizumab 9X-Rays 9Surgical Procedures, Operative 9Ipilimumab 9Immunoglobulin G 9Drug Therapy 9Capecitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rosiglitazone × Head & Neck × 90 days × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡